Data Article

Caloric vestibular stimulation for the management of motor and non-motor symptoms in Parkinson's disease: Intention-to-treat data

David Wilkinson a,*, Aleksandra Podlewska a, Sarah E. Banducci b, Tracy Pellat-Higgins c, Martin Slade d, Mayur Bodani e, Mohamed Sakel f, Lanty Smith b, Peter LeWitt g, Kristen Ade b

a School of Psychology, University of Kent, Canterbury, UK
b Scion NeuroStim, LLC, Durham, NC, USA
c Centre for Health Services Studies, University of Kent, Canterbury, UK
d Yale University, School of Public Health, New Haven, CT 06510, USA
e Neuropsychiatry Service, Kent & Medway NHS and Social Care Partnership Trust, UK
f East Kent Neuro-Rehabilitation Service, East Kent Hospitals University NHS Foundation Trust, Canterbury, UK
g Parkinson’s Disease & Movement Disorders Program, Henry Ford Hospital, Wayne State University School of Medicine, West Bloomfield, MI 48322, USA

ARTICLE INFO

Article history:
Received 23 May 2019
Received in revised form 20 June 2019
Accepted 1 July 2019
Available online 8 July 2019

Keywords:
Non-invasive brain stimulation
Sensory neuro-modulation
Neuro-rehabilitation
Cognition

ABSTRACT

This report provides data related to the safety and effectiveness of repeated time-varying caloric vestibular stimulation (CVS) as a treatment for motor and non-motor features of Parkinson's disease (PD). Forty-six subjects receiving stable anti-Parkinsonian therapy were randomized to active (n = 23) or placebo (n = 23) treatment arms. Subjects self-administered CVS twice-daily over a period of 8 weeks at home via a portable, pre-programmed, solid-state ThermoNeuroModulation (TNM™) device delivering continually-varying thermal waveforms through aluminium ear-probes mounted on a wearable headset. Change scores from baseline to end of treatment and to a 1-month follow-up were determined using standardized clinical measures. The data presented here report sample demographics, detailed safety data and the
These data describe the demographic profile of all randomized subjects as well as measures evaluating the safety and effectiveness of the intervention. Fig. 1 shows the number of participants randomized and subsequently entered into the per-protocol, intention-to-treat, and modified intention-to-treat (i.e. participants who completed the first but not second scheduled assessment during treatment) analyses. Fig. 2 shows the thermal profiles of the stimulation waveforms received by active and sham participants and also illustrates an individual undergoing treatment. Table 1 provides the demographic and clinical characteristics of the participants at baseline. Tables 2 and 3 show the intention-to-treat and modified-intention-to-treat statistical outcomes. Table 4 summarizes the adverse events and their likely relation to study participation.
2. Experimental design, materials, and methods

PD patients were recruited from West and East Kent clinical neuroscience services and through the national PD charity Parkinson’s UK. Eligibility criteria included the diagnosis of PD by the UK Parkinson’s Disease Society Brain Bank Criteria along with reported limitations in activities of daily living. Additionally, patients needed to be receiving stable doses of dopaminergic drugs. Patients with previous exposure to neurostimulation or who were experiencing inner ear pathology were excluded.

![Fig. 1. Consort flow diagram.](image)

![Fig. 2. Target and actual thermal waveform profiles recorded by thermistors located within the aluminium ear pieces for a) an active treatment and b) a placebo treatment, and c) a schematic of a patient undergoing treatment while wearing the CVS headset and lying on an incline wedge pillow. Schematic: Copyright (2016) Wiley. Used with permission from [1].](image)
2.1. Study design

Eligible subjects completed a 4-week baseline evaluation comprising assessments repeated in the first and fourth week and then were randomized (1:1) to active and placebo treatment groups. Subjects self-administered CVS at home (or if needed, with the help of a caregiver) for 8 weeks. Behavioral assessments were performed midway through the treatment period, at the end of treatment period and then 5 weeks after treatment cessation. All evaluations were conducted by the same blinded clinical researcher in subjects’ homes.

Ethical approval was obtained from the East Midlands NHS research ethics committee, and written informed consent was obtained from all subjects at study enrolment. The study was pre-registered at ClinicalTrials.gov as NCT02703844.
Table 2
Intention-to-treat statistical results. Therapeutic gains are calculated as Active - Placebo group change scores. +Medians and median difference (based on all possible differences) and non-parametric Hodges-Lehmann confidence intervals. *Statistically significant (p < 0.05); † exceeds minimal clinically important difference (MCID). End of treatment assessment (week 12), 5 week post-treatment follow up assessment (week 17). Abbreviations: Non-Motor Aspects of Experiences of Daily Living (nM-EDL), Motor Aspects of Experiences of Daily Living (M-EDL). □ Denotes normal distributions at week 12 and non-normal distributions at week 17. ◊ Denotes non-normal distributions at week 12 and normal distributions at week 17.

| Outcome Measure | Change from baseline at week 12 | Change from baseline at week 17 |
|-----------------|---------------------------------|---------------------------------|
|                 | Active                          | Placebo                         | Therapeutic Gains | 95% CI | Active                          | Placebo                         | Therapeutic Gains | 95% CI |
| **Sample size** | 23                              | 23                              |                   |        | 23                              | 23                              |                   |        |
| **Movement Disorder Society Sponsored Unified Parkinson’s Disease Rating Scale** | | | | | | | | |
| Part I: nM-EDL+ | −33.5                           | 0.0                             | −28.5*             | −35.5 to −6.5 | −37.5 to 1.0 | −32.5*             | 47.0 to −13.0 |
| Part II: M-EDL  | −3.4                            | −0.5                            | −2.9*              | −4.9 to −0.9 | −3.0 to −2.7 | −2.7*              | −5.3 to −0.7 |
| Part III: Motor exam | −8.5                            | −3.1                            | −5.3*              | −10.6 to 0.0 | −9.2 to 1.7 | −10.9*             | −16.4 to −5.5 |
| Postural Instability/gait difficulty + | 0.0                             | 0.0                             | −0.5               | −1.5 to 0.5 | −0.5 to −1.0 | −1.0*              | −2.0 to 0.0 |
| **Non-Motor Symptom Scale** | | | | | | | | |
| Total Score+    | −2.5                            | 0.0                             | −2.0               | −5.5 to 1.0 | −3.4 to −0.9 | −2.6*              | −5.5 to −0.4 |
| Domain 1: Cardiovascular + | 0.0                             | 0.0                             | 0.0 to 3.0         | 0.0 to 0.0 | 0.0 to 0.0 | 0.0 to 0.0         | 0.0 to 1.5 |
| Domain 2: Sleep/fatigue+ | −2.5                            | −1.0                            | −2.0               | −5.0 to 2.0 | −5.0 to −2.5 | −7.0               | −7.0 to 0.0 |
| Domain 3: Mood/cognition | −7.2                            | 2.1                             | −9.3*              | −15.5 to −3.2 | −6.9 to 2.8 | −9.7*              | −15.6 to −3.7 |
| Domain 4: Perceptual + | 0.0                             | 0.0                             | 0.0 to 0.0         | 0.0 to 0.0 | 0.0 to 0.0 | 0.0 to 0.0         | 0.0 to 0.0 |
| Domain 5: Attention/memory □ | −3.9                            | 0.4                             | −4.3*              | −8.0 to −0.6 | −1.0 to 0.0 | −4.5*              | −11.5 to 0.0 |
| Domain 6: Gastrointestinal tract(◊) | −2.5                            | 0.0                             | −2.0               | −5.5 to 1.0 | −3.4 to −0.9 | −2.6*              | −5.5 to −0.4 |
| Domain 7: Urinary □ | −4.7                            | −0.5                            | −4.2*              | −7.9 to −0.4 | −3.0 to 0.0 | −3.0               | −7.5 to 0.0 |
| Domain 8: Sexual function + | 0.0                             | 0.0                             | −2.5*              | −3.0 to 0.0 | 0.0 to 0.0 | −3.0*              | −4.0 to 0.0 |
| Domain 9: Miscellaneous | 0.0                             | 0.0                             | −2.0               | −2.0 to 1.5 | 0.0 to 0.0 | −1.0               | −3.5 to 1.0 |
| **Montreal Cognitive Assessment** | | | | | | | | |
| Total Score+    | 1.5                             | 0.0                             | 1.5*               | 0.0 to 2.5 | 1.5 to 0.0 | 1.5*               | 0.5 to 3.0 |
| Anxiety Score+  | 0.0                             | −0.5                            | 0.0 to 0.5         | 0.0 to 0.0 | 0.0 to 0.0 | −1.0               | −2.5 to 0.0 |
| Depression Score+ | −0.5                           | 0.0                             | −0.5               | −1.5 to 0.0 | 0.0 to 0.0 | −1.0               | −3.0 to −0.0 |
| **Epworth Sleepiness Scale** | | | | | | | | |
| Total Score□    | −1.5                            | 0.2                             | −1.7               | −3.7 to 0.3 | 0.0 to 0.0 | −0.5               | −2.5 to 1.0 |
| **Fatigue Severity Scale** | | | | | | | | |
| Total Score     | −3.4                            | −1.1                            | −2.4               | −8.0 to 3.2 | −3.4 to −1.1 | −2.4               | −8.0 to 3.2 |
| **Timed-up-and-go** | | | | | | | | |
| Time to complete + | −1.1                            | 0.0                             | −1.3               | −3.7 to 0.5 | −0.9 to 0.0 | −0.7               | −2.7 to 1.1 |
| **10 m walk**   | | | | | | | | |
| Self-paced walk time (seconds) + | −0.6                            | 0.0                             | −0.6*              | −1.2 to −0.7 | −0.6 to 0.1 | −1.0*              | −1.7 to −0.4 |
| Fast-paced walk time (seconds) | 0.2                             | 0.2                             | 0.0                | −0.4 to 0.4 | 0.2 to 0.3 | −0.0*              | −0.4 to 0.4 |
| **2 minute walk** | | | | | | | | |
| Distance (meters) | 0.3                             | −1.7                            | 2.0                | −7.7 to 11.8 | 4.8 to −3.8 | 8.6                | −0.4 to 17.5 |
| **Parkinson’s Disease Questionnaire - 39** | | | | | | | | |
| Summary Index Score+ | −6.6                            | −0.4                            | −2.6               | −7.0 to 0.6 | −6.9 to −2.3 | −4.6               | −9.3 to 0.0 |
| Modified Schwab and England Activities of Daily Living Scale | | | | | | | | |
| Total Score+    | 4.0                             | 0.0                             | 4.0                | 0.0 to 10.0 | 5.0 to 0.0 | 5.0*               | 0.5 to 10.0 |
| **EQ-SD-5L**    | | | | | | | | |
| Index Score◊    | 0.02                            | 0.01                            | 0.02               | −0.03 to 0.08 | 0.01 to −0.01 | 0.03               | −0.05 to 0.10 |
| **SF-12 Health Survey** | | | | | | | | |
| Physical Composite Score◊ | 1.7                             | 0.0                             | 2.1                | −0.9 to 6.4 | 2.1 to 0.6 | 1.6                | −2.5 to 5.7 |
| Mental Health Composite Score◊ | 0.0                             | 0.0                             | 1.8                | −2.4 to 5.5 | 2.2 to −0.9 | 3.0                | −1.4 to 7.4 |
**Table 3**

Modified intention-to-treat statistical results. Therapeutic gains are calculated as Active - Placebo group change scores.

*Medians and median difference (based on all possible differences) and non-parametric Hodges-Lehmann confidence intervals.

Statistically significant \( p < 0.05 \), \( \delta \) exceeds minimal clinically important difference (MCID). End of treatment assessment (week 12), 5 week post-treatment follow up assessment (week 17). Abbreviations: Non-Motor Aspects of Experiences of Daily Living (nM-EDL), Motor Aspects of Experiences of Daily Living (M-EDL).

| Outcome Measure | Change from baseline at week 12 | Change from baseline at week 17 |
|-----------------|-------------------------------|-------------------------------|
|                 | Active Mean | Placebo Mean | Therapeutic Mean | 95% CI | Active Mean | Placebo Mean | Therapeutic Mean | 95% CI |
| **Sample size** | 17 | 19 | 17 | 19 |
| **Movement Disorder Society Sponsored Unified Parkinson’s Disease Rating Scale** | | | | | | | | |
| Part I: nM-EDL | -4.9 | -2.1 | -2.9 | -5.7 to 0.0 | -5.5 | -0.2 | -5.3* | -7.9 to -2.7 |
| Part II: M-EDL | -4.7 | -0.5 | -4.2* | -6.4 to -2.0 | -4.1 | -0.2 | -3.9* | -6.6 to -1.2 |
| Part III: Motor exam | -11.4 | -3.9 | -7.5* | -13.2 to -1.8 | -12.4 | 2.1 | -14.5* | -20.2 to -8.8 |
| Postural Instability/ gait difficulty | -1.0 | 0.0 | -0.5 | -2.5 to 1.0 | -1.7 | -0.5 | -1.1* | -3.0 to -0.7 |
| **Non-Motor Symptom Scale** | | | | | | | | |
| Total Score | -36.1 | -4.6 | -31.5* | -49.5 to -13.5 | -38.9 | 0.7 | -39.6* | 56.0 to -23.2 |
| Domain 1: Cardiovascular + | 0.0 | 0.0 | 1.5 | 0.0 to 3.5 | 0.0 | 0.0 | 0.5 | 0.0 to 3.0 |
| Domain 2: Sleep/fatigue | -5.8 | -4.4 | -1.4 | -6.0 to 3.2 | -7.5 | -2.6 | -4.8* | -7.8 to -1.9 |
| Domain 3: Mood/cognition | -10.8 | 3.4 | -14.2* | -21.8 to -6.5 | -10.3 | 4.3 | -14.6* | -22.0 to -7.2 |
| Domain 4: Perceptual + | 0.0 | 0.0 | 0.0 | -1.0 to 0.5 | 0.0 | 0.0 | 0.0 | 0.0 to 0.5 |
| Domain 5: Attention/memory | -6.0 | -0.3 | -5.7* | -10.3 to -1.1 | -6.7 | 1.9 | -8.7* | -13.3 to -4.0 |
| Domain 6: Gastrointestinal tract | -5.2 | -2.3 | -2.9 | -7.2 to 1.5 | -5.5 | -1.5 | -4.0* | -7.4 to -0.6 |
| Domain 7: Urinary | -6.6 | -1.3 | -5.3* | -10.4 to -0.2 | -6.9 | -2.8 | -3.7 | -9.1 to 1.7 |
| Domain 8: Sexual function + | -1.8 | 0.0 | -3.0* | -5.0 to 0.0 | 0.0 | 0.0 | -3.0* | -6.0 to 0.0 |
| Domain 9: Miscellaneous | -3.1 | -0.6 | -2.5 | -5.5 to 0.6 | -2.8 | 1.1 | -3.9* | -7.0 to -0.8 |
| **Montreal Cognitive Assessment** | | | | | | | | |
| Total Score | 2.5 | 0.4 | 2.0* | 0.8 to 3.2 | 2.6 | -0.2 | 2.7* | 1.4 to 4.0 |
| **Hospital Anxiety and Depression Scale** | | | | | | | | |
| Anxiety Score | -1.5 | -0.3 | -1.2 | -2.9 to 0.5 | -2.5 | -0.1 | -2.5* | -4.2 to -0.8 |
| Depression Score | -1.4 | -0.2 | -1.1 | -2.5 to 0.2 | -1.1 | 0.7 | -1.9 | -3.7 to -0.1 |
| **Epworth Sleepiness Scale** | | | | | | | | |
| Total Score | -2.0 | 0.2 | -2.2 | -4.9 to 0.5 | -1.3 | -0.8 | -0.5 | -3.1 to 2.1 |
| **Fatigue Severity Scale** | | | | | | | | |
| Total Score | -4.6 | -1.3 | -3.4 | -10.2 to 3.4 | -6.1 | -0.2 | -5.9 | -12.0 to 0.2 |
| Timed-up-and-go | -1.7 | -0.2 | -1.9 | -5.6 to 0.8 | -2.2 | 0.2 | -1.5 | -4.3 to 2.3 |
| **10 m walk** | | | | | | | | |
| Self-paced walk time (seconds) + | -0.8 | 0.0 | -0.9* | -1.8 to -0.3 | -0.8 | 0.5 | -1.4* | -2.7 to -0.6 |
| Fast-paced walk time (seconds) | 0.2 | 0.2 | 0.0 | -0.5 to 0.6 | 0.3 | 0.3 | 0.0 | -0.6 to 0.5 |
| **2 minute walk** | | | | | | | | |
| Distance (meters) | 0.2 | -2.0 | 2.3 | -10.3 to 14.8 | 5.9 | -4.3 | 10.2 | -1.2 to 21.6 |
| **Summary Index Score** | -7.5 | -4.4 | -3.2 | -7.9 to 1.6 | -6.9 | -2.3 | -4.6 | -9.3 to 0.0 |
| **Modified Schwab and England Activities of Daily Living Scale** | | | | | | | | |
| Total Score | 7.5 | 0.0 | 7.5* | 0.0 to 15.0 | 7.5 | 0.0 | 7.5* | 2.5 to 15.0 |
| EQ-5D-5L | 0.07 | 0.05 | 0.03 | -0.05 to 0.10 | 0.02 | -0.02 | 0.04 | -0.06 to 0.13 |
| **SF-12 Health Survey** | | | | | | | | |
| Physical Composite Score | 4.8 | 1.0 | 3.8 | -0.9 to 8.4 | 2.9 | 0.7 | 2.2 | -2.8 to 7.1 |
| Mental Health | 2.8 | 0.0 | 2.8 | -2.1 to 7.6 | 2.9 | -1.0 | 3.9 | -1.3 to 9.2 |
| **Composite Score** | | | | | | | | |

D. Wilkinson et al. / Data in brief 25 (2019) 104228
2.2. Stimulation protocol

For device treatments, subjects were instructed to lie on a 22°-elevated wedge pillow to orient the horizontal semi-circular canal vertically (thereby maximizing vestibular activation). Subjects self-administered CVS treatments twice daily using the solid-state TNM™ device previously described [2,3], and were instructed to separate the two daily treatments by at least 1 hour. Active treatment involved the simultaneous delivery of a time-varying, warm, saw-tooth thermal (37°C–42°C) stimulus to one ear and a cold saw-tooth thermal (37°C–17°C) stimulus to the other ear for approximately 19 minutes (Fig. 2). Every 2 days, the warm and cold waveforms were switched between left and right ears to avoid the possible induction of a long-term, lateralized asymmetry in vestibular function. By slow warming and cooling of inner ear structures, it was possible to avoid vertigo and nausea that can result from chilled water irrigation used in the clinical testing of brainstem function. In the placebo testing condition, subjects underwent the same treatment choreography and experienced the same visual and auditory stimuli associated with running a treatment though no power was delivered to the heating and cooling elements. To maintain treatment blinding, treatment was discussed as brainstem modulation and no reference to the thermal stimulus was made. Subjects were told that they might or might not feel temperature changes in their ears (and that this would not be an indicator of active or placebo treatment; rather, temperature changes are naturally felt by some people and not by others). Subjects were told that they had a 50% likelihood of receiving either placebo or active treatment.

2.3. Validated outcome measures

Assessments were performed in the ON medication state (subjects reporting full medication effect against their Parkinsonism) and always timed to occur at the same time relative to the last dose of dopaminergic therapy. Outcome measures included the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) [4], the Postural Instability and Gait Dysfunction score from the MDS-UPDRS [5], the Non-Motor Symptom Scale for PD [6], the Modified Schwab and England...
Activities of Daily Living Scale [7], the 2 minute walk test [8], the Timed-Up-and-Go test [9], the 10 m walk test [10], the Montreal Cognitive Assessment [11], the Hospital Anxiety and Depression Scale [12] the EQ-5D-5L [13], Epworth Sleepiness Scale [14], the Fatigue Severity Scale [15], the mental component summary score and physical component summary score of the Short-Form 12 (SF-12) [16] and the Parkinson’s Disease Questionnaire-39 index summary score [17].

2.4. Statistical analyses

Analysis was conducted on the Intention-to-treat (ITT) dataset at the end of active treatment and at 5-week follow-up and included all randomized subjects (n = 46). Additional analysis was conducted on the modified intention-to-treat (mITT) data which included only those participants who completed the midway- but not end-of-treatment assessment. Results from the per protocol cohort are reported elsewhere [1]. Outcomes were analyzed using analysis of covariance (ANCOVA) to compare the change in the mean response (from the average of week 1 and 4 baseline scores) across treatment groups using an alpha of 0.05. The outcomes were adjusted for baseline symptom severity by including the baseline measure as a covariate. Outcomes with non-normal distributions were analyzed using Wilcoxon Rank Sum tests to compare the median change in response across treatment groups and the Hodges-Lehmann method was used to calculate median difference and confidence intervals. The Last Observation Carried Forward (LOCF) method was used to estimate missing values. The results are presented in Tables 2 and 3. Analysis was performed using SAS 9.4 (SAS Institute, Cary, NC, USA).

All randomized subjects were monitored for adverse events (AEs). Thirty four AEs were recorded, including 24 AEs in the active arm and 10 AEs in the placebo arm (Table 4). The likely cause of all AEs was determined by independent medical adjudication. All AEs that were deemed as potentially related to device use (n = 5) were non-serious and transient in nature (i.e. ceasing after termination of treatment).

Acknowledgments

We wish to thank all subjects for their patient cooperation and thank Parkinson’s UK, especially those branches in Kent, for helping with subject recruitment. We also wish to thank Saghi Arabi, Maryam Keshavarzi-Pour, Charlotte Wheeler, Kathryn Poynter and Brittany Melin for assistance with clinical data management. This work was partly supported by Scion NeuroStim, LLC.

Conflict of interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Kristen Ade reports receiving compensation and ownership interests in Scion NeuroStim, LLC (SNS), Sarah Banducci reports receiving compensation from SNS and Lanty Smith reports ownership interests in SNS.

References

[1] D. Wilkinson, A. Podlewka, S. Banducci, T. Pellat-Higgins, M. Bodani, M. Sakel, L. Smith, P. LeWitt, K. Ade, Caloric Vestibular Stimulation for the Management of Motor and Non-motor Symptoms in Parkinson’s Disease, Park Relat. Dis. (2019), https://doi.org/10.1016/j.parkreldis.2019.05.031.
[2] R.D. Black, L.L. Rogers, K.K. Ade, H.A. Nicoletto, H.D. Adkins, D.T. Laskowitz, Non-invasive neuromodulation using time-varying caloric vestibular stimulation, IEEE J. Transl Eng. Heath Med. 4 (1) (2016) 10.
[3] D. Wilkinson, K.K. Ade, L.L. Rogers, D.K. Attix, M. Kuchibhatla, M.D. Slade, L.L. Smith, K.P. Poynter, D.T. Laskowitz, M.C. Freeman, M.E. Hoffer, J.R. Saper, D.L. Scott, M. Sakel, A.H. Calhoun, R.D. Black, Preventing episodic migraine with caloric vestibular stimulation: a randomized controlled trial, Headache 57 (7) (2017) 1065–1087.
[4] C.G. Goetz, B.C. Tilley, S.R. Shaftman, G.T. Stebbins, S. Fahn, P. Martinez-Martin, W. Poewe, C. Sampaio, M.B. Stern, R. Dodel, B. Dubois, R. Holloway, J. Jankovic, J. Kulisevsky, A.E. Lang, A. Lees, S. Leurgans, P.A. LeWitt, D. Nyenhuis, C.W. Olanow, O. Rascol, A. Schrag, J.A. Teresi, J.J. van Hilten, N. LaPelle, U.R.T.F. Movement Disorder Society, Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results, Mov. Disord. 23 (15) (2008) 2129–2170.
B.R. Bloem, J. Marinus, Q. Almeida, L. Dibble, A. Nieuwboer, B. Post, E. Ruzicka, C. Goetz, G. Stebbins, P. Martinez-Martin, A. Schrag, C. movement disorders society rating scales, measurement instruments to assess posture, gait, and balance in Parkinson’s disease: critique and recommendations, Mov. Disord. 31 (9) (2016) 1342–1355.

K.R. Chaudhuri, P. Martinez-Martin, R.G. Brown, K. Sethi, F. Stocchi, P. Odn, W. Ondo, K. Abe, G. Macphee, D. Macmahon, P. Barone, M. Rabey, A. Forbes, K. Breen, S. Tluk, Y. Naidu, W. Olano, A.J. Williams, S. Thomas, D. Rye, Y. Tsuboi, A. Hand, A.H. Schapira, The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study, Mov. Disord. 22 (13) (2007) 1901–1911.

R.S. Schwab, A.C. England, Projection Technique for Evaluating Suyergy in Parkinson’s Disease, 1969, pp. 152–157.

R.J. Butland, J. Pang, E.R. Gross, A.A. Woodcock, D.M. Geddes, Two-, six-, and 12-minute walking tests in respiratory disease, Br. Med. J. 284 (6325) (1982) 1607–1608.

D. Podsiadlo, S. Richardson, The timed “Up & Go”: a test of basic functional mobility for frail elderly persons, J. Am. Geriatr. Soc. 39 (2) (1991) 142–148.

T. Steffen, M. Seney, Test-retest reliability and minimal detectable change on balance and ambulation tests, the 36-item short-form health survey, and the unified Parkinson disease rating scale in people with parkinsonism, Phys. Ther. 88 (6) (2008) 733–746.

Z.S. Nasreddine, N.A. Phillips, V. Bedirian, S. Charbonneau, V. Whitehead, I. Collin, J.L. Cummings, H. Chertkow, The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment, J. Am. Geriatr. Soc. 53 (4) (2005) 695–699.

A.S. Zigmond, R.P. Snaith, The hospital anxiety and depression scale, Acta Psychiatr. Scand. 67 (6) (1983) 361–370.

M. Herdman, C. Gudex, A. Lloyd, M. Janssen, P. Kind, D. Parkin, G. Bonsel, X. Badia, Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L), Qual. Life Res. 20 (10) (2011) 1727–1736.

M.W. Johns, A new method for measuring daytime sleepiness: the Epworth sleepiness scale, Sleep 14 (6) (1991) 540–545.

L.B. Krupp, N.G. LaRocca, J. Muir-Nash, A.D. Steinberg, The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus, Arch. Neurol. 46 (10) (1989) 1121–1123.

C. Jenkinson, R. Layte, Development and testing of the UK SF-12 (short form health survey), J. Health Serv. Res. Policy 2 (1) (1997) 14–18.

C. Jenkinson, R. Fitzpatrick, V. Peto, R. Greenhall, N. Hyman, The parkinson’s disease questionnaire (PDQ-39): development and validation of a parkinson’s disease summary index score, Age Ageing 26 (5) (1997) 353–357.